Healthcare Industry News: metabolic disease
News Release - October 3, 2006
Amylin Pharmaceuticals Appoints Joe Young Sr. Vice President, MarketingSAN DIEGO, Oct. 3 (HSMN NewsFeed) -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) announced today that Joe A. Young has been appointed Sr. Vice President, Marketing. Mr. Young brings a breadth of experience across multiple commercial roles, including new product planning, product launches, brand management, sales and sales management. His last 10 years have been focused on diabetes and other metabolic diseases, with leadership roles in the commercialization of thiazolidinediones and injectable and inhaled insulins.
Before joining Amylin, Mr. Young was Vice President, Diabetes Brand Marketing at Novo Nordisk, where he managed a full scope of marketing activities for their diabetes business. Previously, Mr. Young was Director, Global Marketing and Medical for Aventis and led the global launch of Lantus -- the company's leading diabetes product.
"Joe brings a wealth of knowledge and experience about diabetes and the activities required to introduce new and innovative medicines to the largest healthcare market in the world. His passion for introducing new options to patients and healthcare professionals coupled with his wide array of experiences will continue to build on Amylin's successful launch of two first-in-class medicines for diabetes," said Ginger L. Graham, Amylin's Chief Executive Officer.
Mr. Young will become a member of Amylin's senior management team and replaces Dwayne M. Elwood, who will continue with Amylin as an Executive Advisor. "Dwayne has been instrumental in building the commercial organization from the ground up. We appreciate his market insight, professionalism, commitment and focus on patients," commented Ms. Graham. "His guidance throughout the organization during his nearly four years as head of Marketing at Amylin has been invaluable."
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1250 employees nationwide. Further information on Amylin Pharmaceuticals is available at www.amylin.com.
This press release contains forward-looking statements about Amylin. The company's actual results could differ materially from those discussed in this press release due to a number of risks and uncertainties, including those described in the company's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.
Source: Amylin Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.